Insufficient scRNA-seq data for expression of SLC47A2 at single-cell level.
Insufficient scRNA-seq data for expression of SLC47A2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 6583.90 | 89 / 89 | 46% | 10.83 | 418 / 901 |
brain | 68% | 301.81 | 1807 / 2642 | 56% | 4.94 | 392 / 705 |
adrenal gland | 98% | 59.55 | 253 / 258 | 1% | 0.02 | 3 / 230 |
esophagus | 45% | 56.52 | 644 / 1445 | 40% | 2.44 | 74 / 183 |
thymus | 74% | 26.83 | 481 / 653 | 6% | 0.75 | 36 / 605 |
skin | 72% | 308.60 | 1300 / 1809 | 4% | 0.09 | 19 / 472 |
uterus | 36% | 50.38 | 62 / 170 | 27% | 1.57 | 122 / 459 |
muscle | 56% | 98.41 | 446 / 803 | 0% | 0 | 0 / 0 |
prostate | 49% | 14.65 | 120 / 245 | 2% | 0.05 | 8 / 502 |
lung | 23% | 5.99 | 132 / 578 | 22% | 1.20 | 259 / 1155 |
breast | 42% | 23.12 | 195 / 459 | 1% | 0.04 | 12 / 1118 |
ovary | 22% | 6.06 | 40 / 180 | 17% | 0.38 | 73 / 430 |
tonsil | 0% | 0 | 0 / 0 | 31% | 1.63 | 14 / 45 |
intestine | 31% | 16.66 | 298 / 966 | 0% | 0.01 | 1 / 527 |
blood vessel | 19% | 6.18 | 252 / 1335 | 0% | 0 | 0 / 0 |
adipose | 19% | 6.50 | 226 / 1204 | 0% | 0 | 0 / 0 |
liver | 15% | 3.81 | 35 / 226 | 3% | 0.07 | 13 / 406 |
pancreas | 9% | 2.88 | 30 / 328 | 2% | 0.03 | 3 / 178 |
stomach | 8% | 2.08 | 30 / 359 | 1% | 0.02 | 3 / 286 |
spleen | 8% | 1.87 | 20 / 241 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 8% | 0.99 | 40 / 504 |
heart | 5% | 2.14 | 44 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 0.06 | 3 / 80 |
peripheral blood | 0% | 0.05 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1902600 | Biological process | proton transmembrane transport |
GO_1990961 | Biological process | xenobiotic detoxification by transmembrane export across the plasma membrane |
GO_0015695 | Biological process | organic cation transport |
GO_0055085 | Biological process | transmembrane transport |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0042910 | Molecular function | xenobiotic transmembrane transporter activity |
GO_0015297 | Molecular function | antiporter activity |
GO_0140968 | Molecular function | polyspecific organic cation:proton antiporter activity |
GO_0015101 | Molecular function | organic cation transmembrane transporter activity |
GO_0022857 | Molecular function | transmembrane transporter activity |
Gene name | SLC47A2 |
Protein name | Multidrug and toxin extrusion protein 2 (MATE-2) (hMATE-2) (Kidney-specific H(+)/organic cation antiporter) (Solute carrier family 47 member 2) Multidrug and toxin extrusion protein 2 |
Synonyms | MATE2 |
Description | FUNCTION: Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. Mediates the efflux of endogenous compounds such as, creatinine, thiamine and estrone-3-sulfate. Plays a physiological role in the excretion of drugs, toxins and endogenous metabolites through the kidney. .; FUNCTION: [Isoform 6]: Non-functional protein. . |
Accessions | ENST00000350657.9 [Q86VL8-4] ENST00000433844 Q86VL8 ENST00000433844.4 [Q86VL8-3] ENST00000574239.5 [Q86VL8-6] ENST00000325411.9 [Q86VL8-1] C9JAE6 |